Synaptogenix (NASDAQ:TAOX) & Clever Leaves (NASDAQ:CLVR) Critical Analysis

Clever Leaves (NASDAQ:CLVR) and Synaptogenix (NASDAQ:TAOX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Clever Leaves has a beta of 4121.19, suggesting that its stock price is 412,019% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.

Profitability

This table compares Clever Leaves and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Synaptogenix	N/A	-240.92%	-150.03%

Valuation and Earnings

This table compares Clever Leaves and Synaptogenix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42 million	0.00	-$17.90 million	($12.36)	N/A
Synaptogenix	N/A	N/A	-$12.77 million	($20.16)	-0.19

Synaptogenix has lower revenue, but higher earnings than Clever Leaves. Synaptogenix is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Clever Leaves and Synaptogenix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clever Leaves	0	0	0	0	0.00
Synaptogenix	1	0	0	0	1.00

Given Clever Leaves’ higher probable upside, research analysts plainly believe Clever Leaves is more favorable than Synaptogenix.

Summary

Clever Leaves beats Synaptogenix on 8 of the 11 factors compared between the two stocks.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.